Targeting microtubule dynamics to treat advanced prostate cancer
Official title: Targeted Suppression of Microtubule Dynamics for Treatment of Metastatic Castration-Resistant Prostate Cancer
Funded at University of Texas Hlth Sci Ctr Houston · NIH-11167485 · Data updated 2026-11-12
This study is testing a new treatment for men with advanced prostate cancer that doesn't respond to hormone therapy, using special molecules that target cancer cells to help improve the effectiveness of the therapy while protecting healthy tissue, and you might have a chance to join the trials to see how well it works.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Sci Ctr Houston NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | April 15, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $571,271 |
| NIH project number | 1R01CA298343-01A1 |
| Project ID | NIH-11167485 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with metastatic castration-resistant prostate cancer who have not responded adequately to existing therapies.
✕Less likely to help
Patients with early-stage prostate cancer or those who are not castration-resistant may not benefit from this research.
What this research studies
This research aims to develop a new targeted therapy for metastatic castration-resistant prostate cancer (mCRPC), a condition with limited treatment options and poor survival rates. The approach focuses on utilizing small molecules that specifically bind to the prostate-specific membrane antigen (PSMA), which is overexpressed in cancerous prostate tissue. By employing advanced radionuclide therapy, the research seeks to enhance the effectiveness of treatment while minimizing damage to non-cancerous tissues. Patients may have the opportunity to participate in trials that evaluate the safety and efficacy of these innovative therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with advanced prostate cancer, potentially improving survival rates and quality of life.
How similar studies have gone: Previous research has shown promising results with similar targeted therapies, but this specific approach is still being evaluated for its effectiveness.
Where this research is happening
-
University of Texas Hlth Sci Ctr Houston
Houston, United States Active
Researchers
- Principal investigator: Azhdarinia, Ali — University of Texas Hlth Sci Ctr Houston
- Study coordinator: Azhdarinia, Ali
Related research
Other NIH-funded projects on the same topics.
-
Understanding how aggressive cell states emerge in castration-resistant prostate cancer
A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.
-
Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer
Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.
-
Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer
Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.
-
Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy
This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.
-
Hyperactive methylation in a hard-to-treat prostate cancer subtype
Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.
-
Therapeutic Targeting of Lineage Plasticity in Advanced Prostate Cancer
A cancer research effort aimed at understanding and tackling how aggressive prostate cancers become resistant to standard AR-targeted therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.